Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 29

1.

Dynamic role of the codon 72 p53 single-nucleotide polymorphism in mammary tumorigenesis in a humanized mouse model.

Gunaratna RT, Santos A, Luo L, Nagi C, Lambertz I, Spier M, Conti CJ, Fuchs-Young RS.

Oncogene. 2019 May;38(18):3535-3550. doi: 10.1038/s41388-018-0630-4. Epub 2019 Jan 16.

2.

Early Exposure to a High Fat/High Sugar Diet Increases the Mammary Stem Cell Compartment and Mammary Tumor Risk in Female Mice.

Lambertz IU, Luo L, Berton TR, Schwartz SL, Hursting SD, Conti CJ, Fuchs-Young R.

Cancer Prev Res (Phila). 2017 Oct;10(10):553-562. doi: 10.1158/1940-6207.CAPR-17-0131. Epub 2017 Sep 13.

3.

Culture of Tumorigenic Cells on Protein Fibers Reveals Metastatic Cell Behaviors.

Hsiao HC, Santos A, Howell DW, Patterson JL, Fuchs-Young RS, Bondos SE.

Biomacromolecules. 2016 Nov 14;17(11):3790-3799. Epub 2016 Oct 17.

PMID:
27653640
4.

Developmental stage determines estrogen receptor alpha expression and non-genomic mechanisms that control IGF-1 signaling and mammary proliferation in mice.

Tian J, Berton TR, Shirley SH, Lambertz I, Gimenez-Conti IB, DiGiovanni J, Korach KS, Conti CJ, Fuchs-Young R.

J Clin Invest. 2012 Jan;122(1):192-204. doi: 10.1172/JCI42204. Epub 2011 Dec 19.

5.

Transgenic insulin-like growth factor-1 stimulates activation of COX-2 signaling in mammary glands.

Tian J, Lambertz I, Berton TR, Rundhaug JE, Kiguchi K, Shirley SH, Digiovanni J, Conti CJ, Fischer SM, Fuchs-Young R.

Mol Carcinog. 2012 Dec;51(12):973-83. doi: 10.1002/mc.20868. Epub 2011 Oct 17.

6.

P53 genotype as a determinant of ER expression and tamoxifen response in the MMTV-Wnt-1 model of mammary carcinogenesis.

Fuchs-Young R, Shirley SH, Lambertz I, Colby JK, Tian J, Johnston D, Gimenez-Conti IB, Donehower LA, Conti CJ, Hursting SD.

Breast Cancer Res Treat. 2011 Nov;130(2):399-408. doi: 10.1007/s10549-010-1308-y. Epub 2010 Dec 30.

7.

Addressing cancer health disparities using a global biopsychosocial approach.

King D, Miranda P, Gor B, Fuchs-Young R, Chilton J, Hajek R, Torres-Vigil I, Hernández-Valero MA, Snipes SA, Jones L.

Cancer. 2010 Jan 15;116(2):264-9. doi: 10.1002/cncr.24765.

8.

Exercise effects on tumorigenesis in a p53-deficient mouse model of breast cancer.

Colbert LH, Westerlind KC, Perkins SN, Haines DC, Berrigan D, Donehower LA, Fuchs-Young R, Hursting SD.

Med Sci Sports Exerc. 2009 Aug;41(8):1597-605. doi: 10.1249/MSS.0b013e31819f1f05.

9.

Transcriptional regulation of estrogen receptor-alpha by p53 in human breast cancer cells.

Shirley SH, Rundhaug JE, Tian J, Cullinan-Ammann N, Lambertz I, Conti CJ, Fuchs-Young R.

Cancer Res. 2009 Apr 15;69(8):3405-14. doi: 10.1158/0008-5472.CAN-08-3628. Epub 2009 Apr 7.

10.

Public talks and science listens: a community-based participatory approach to characterizing environmental health risk perceptions and assessing recovery needs in the wake of hurricanes katrina and rita.

Sullivan J, Parras B, St Marie R, Subra W, Petronella S, Gorenstein J, Fuchs-Young R, Santa RK, Chavarria A, Ward J, Diamond P.

Environ Health Insights. 2009 Jun 23;3:37-51.

11.

Paracrine overexpression of insulin-like growth factor-1 enhances mammary tumorigenesis in vivo.

de Ostrovich KK, Lambertz I, Colby JK, Tian J, Rundhaug JE, Johnston D, Conti CJ, DiGiovanni J, Fuchs-Young R.

Am J Pathol. 2008 Sep;173(3):824-34. doi: 10.2353/ajpath.2008.071005. Epub 2008 Aug 7.

12.

Increased tumor growth in mice with diet-induced obesity: impact of ovarian hormones.

Yakar S, Nunez NP, Pennisi P, Brodt P, Sun H, Fallavollita L, Zhao H, Scavo L, Novosyadlyy R, Kurshan N, Stannard B, East-Palmer J, Smith NC, Perkins SN, Fuchs-Young R, Barrett JC, Hursting SD, LeRoith D.

Endocrinology. 2006 Dec;147(12):5826-34. Epub 2006 Sep 7.

PMID:
16959846
13.

Differential susceptibility to chemically induced thymic lymphomas in SENCARB and SSIN inbred mice.

Benavides F, Gomez G, Venables-Griffith A, Lambertz I, Flores M, Angel JM, Fuchs-Young R, Richie ER, Conti CJ.

Mol Carcinog. 2006 Jul;45(7):543-8.

PMID:
16479612
14.

Transdominant suppression of estrogen receptor signaling by progesterone receptor ligands in uterine leiomyoma cells.

Hodges LC, Houston KD, Hunter DS, Fuchs-Young R, Zhang Z, Wineker RC, Walker CL.

Mol Cell Endocrinol. 2002 Oct 31;196(1-2):11-20.

PMID:
12385821
15.

An in vivo/in vitro model to assess endocrine disrupting activity of xenoestrogens in uterine leiomyoma.

Hodges LC, Hunter DS, Bergerson JS, Fuchs-Young R, Walker CL.

Ann N Y Acad Sci. 2001 Dec;948:100-11. Review.

PMID:
11795388
16.

Dysregulation of IGF-I signaling in uterine leiomyoma.

Burroughs KD, Howe SR, Okubo Y, Fuchs-Young R, LeRoith D, Walker CL.

J Endocrinol. 2002 Jan;172(1):83-93.

PMID:
11786376
17.
18.

Efficacy of LGD1069 (Targretin), a retinoid X receptor-selective ligand, for treatment of uterine leiomyoma.

Gamage SD, Bischoff ED, Burroughs KD, Lamph WW, Gottardis MM, Walker CL, Fuchs-Young R.

J Pharmacol Exp Ther. 2000 Nov;295(2):677-81.

PMID:
11046105
19.

Influence of exogenous estrogen receptor ligands on uterine leiomyoma: evidence from an in vitro/in vivo animal model for uterine fibroids.

Hunter DS, Hodges LC, Eagon PK, Vonier PM, Fuchs-Young R, Bergerson JS, Walker CL.

Environ Health Perspect. 2000 Oct;108 Suppl 5:829-34. Review.

20.

Preclinical evidence for therapeutic efficacy of selective estrogen receptor modulators for uterine leiomyoma.

Walker CL, Burroughs KD, Davis B, Sowell K, Everitt JI, Fuchs-Young R.

J Soc Gynecol Investig. 2000 Jul-Aug;7(4):249-56.

PMID:
10964025
21.

Estrogen receptor activation via activation function 2 predicts agonism of xenoestrogens in normal and neoplastic cells of the uterine myometrium.

Hunter DS, Hodges LC, Vonier PM, Fuchs-Young R, Gottardis MM, Walker CL.

Cancer Res. 1999 Jul 1;59(13):3090-9.

22.

Effects of raloxifene in a guinea pig model for leiomyomas.

Porter KB, Tsibris JC, Porter GW, Fuchs-Young R, Nicosia SV, O'Brien WF, Spellacy WN.

Am J Obstet Gynecol. 1998 Nov;179(5):1283-7.

PMID:
9822517
23.

Regulation of apoptosis in uterine leiomyomata.

Burroughs KD, Kiguchi K, Howe SR, Fuchs-Young R, Trono D, Barrett JC, Walker C.

Endocrinology. 1997 Jul;138(7):3056-64. Erratum in: Endocrinology 1997 Sep;138(9):3786.

PMID:
9202252
24.

Rapid tumor development with a modified MCF-7 xenograft model.

Hale LV, Layman NK, Wilson P, Short LL, Magee DE, Wightman SR, Fuchs-Young R.

Lab Anim Sci. 1997 Feb;47(1):82-5. No abstract available.

PMID:
9051652
25.

Inhibition of estrogen-stimulated growth of uterine leiomyomas by selective estrogen receptor modulators.

Fuchs-Young R, Howe S, Hale L, Miles R, Walker C.

Mol Carcinog. 1996 Nov;17(3):151-9.

PMID:
8944075
26.

Raloxifene is a tissue-selective agonist/antagonist that functions through the estrogen receptor.

Fuchs-Young R, Glasebrook AL, Short LL, Draper MW, Rippy MK, Cole HW, Magee DE, Termine JD, Bryant HU.

Ann N Y Acad Sci. 1995 Jun 12;761:355-60. No abstract available.

PMID:
7625735
27.

Localization of immunoreactive epidermal growth factor receptor in neonatal and adult rat hippocampus.

Tucker MS, Khan I, Fuchs-Young R, Price S, Steininger TL, Greene G, Wainer BH, Rosner MR.

Brain Res. 1993 Dec 17;631(1):65-71.

PMID:
8298997
28.

Estrogen and progesterone receptor structure and action in breast cancer cells.

Bettuzzi S, Robinson A, Fuchs-Young R, Greene GL.

Cancer Treat Res. 1992;61:301-15. No abstract available.

PMID:
1360239
29.

Supplemental Content

Loading ...
Support Center